| | | | | | | STANDA | RD GLOBAL RE | PORT | | | | | | |
|------|---|---|----|--|------------------------------------|---------------------------------|---|-------------------|---------------------------|---------------------------------|---|--|-------------------|--|
| | Date of publication: 04-September-202 | | | | | | | | | | | | | |
| | Full Name | HCPs: City of Principal Practice HCOs: City where registered | | Principal Practice Address | Unique country identifier OPTIONAL | Donations and Grants to HCOs | Contribution to costs of Events | | | Fee for service and consultancy | | | | |
| | | | | | | | Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event | Registration Fees | Travel & Accommodation | Fees | Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract | | TOTAL OPTIONAL | |
| | INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) | | | | | | | | | | | | | |
| | Iljoska, Marina | Skopje | МК | Majka Tereza 17, JZU UK za Radioterapija i Onkologija | | N/A | N/A | 1,302.50 | | | | | 1,302.50 | |
| HCPs | Lazareva, Emilija | Skopje | MK | Majka Tereza 17, JZU UK za Radioterapija i Onkologija | | N/A | N/A | 1,302.50 | - | | - | | 1,302.50 | |
| | OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons | | | | | | | | | | | | | |
| | Aggregate amount attributable to transfers of value to such Recipients | | | | | N/A | N/A | 1,302.50 | - | | | | 1,302.50 | |
| | Number of Recipients in aggregate disclosure | | | | | N/A | N/A | 1 | - | | | | 1 | |
| | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed | | | | | N/A | N/A | 33.33% | - | | - | | N/A | |
| | INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate) | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| S | OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons | | | | | | | | | | | | | |
| HCOs | Aggregate amount attributable to transfers of value to such Recipients | | | | | | | | | | | | | |
| | Number of Recipients in aggregate disclosure | | | | | | | | | | | | | |
| | % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed | | | | | | | | | | | | N/A | |
| | | | | | | | | | | | | | | |
| 0 | AGGREGATE DISCLOSURE | | | | | | | | | | | | | |
| R&D | Transfers of Value related to Research & Development | | | | | | | | | | | | | |